Valneva SE (VLA):企業の財務・戦略的SWOT分析

◆英語タイトル:Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1664
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥14,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥28,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥43,125見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Valneva SE (VLA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Valneva SE (Valneva) is a biotechnology company that develops lifesaving vaccines against infectious diseases and cancer. The company’s products include a vaccine indicated for the prevention of Japanese encephalitis; and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of lyme, chikungunya, zika virus and infections caused by Clostridium difficile. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline vaccine candidates and to distribute its products. The company sells its products in the Americas, Asia Pacific, Europe and the Middle East. It operates in Austria, Sweden, the UK, France, the US and Canada. Valneva is headquartered in Saint-Herblain, France.

Valneva SE Key Recent Developments

Mar 24,2020 Valneva provides business update on COVID-19 situation
Feb 03,2020 Valneva announces new $85 million financing arrangement with leading US healthcare funds Deerfield and OrbiMed
Jan 09,2020 Valneva Expands its commercial operations with the opening of its French commercial office
Dec 20,2019 Valneva completes delisting from the Vienna Stock Exchange

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Valneva SE – Key Facts
Valneva SE – Key Employees
Valneva SE – Key Employee Biographies
Valneva SE – Major Products and Services
Valneva SE – History
Valneva SE – Company Statement
Valneva SE – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Valneva SE – Business Description
Product Category: Dukoral
Overview
Performance
Key Stats
Product Category: Ixiaro/Jespect
Overview
Performance
Key Stats
Product Category: Other
Performance
Product Category: Revenues from Collaborations, Licensing and Services
Performance
Product Category: Third Party Products
Performance
Product Category: Total Product sales
Performance
Product Category: Commercialized Vaccines
Overview
Performance
Product Category: Technologies and Services
Overview
Performance
Product Category: Vaccine Candidates
Overview
Performance
Geographical Segment: Austria
Performance
Geographical Segment: Canada
Capital Expenditure
Geographical Segment: Germany
Performance
Geographical Segment: Nordics
Capital Expenditure
Geographical Segment: Other Europe
Performance
Geographical Segment: Other markets
Performance
Geographical Segment: Switzerland
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
Valneva SE – Corporate Strategy
Valneva SE – SWOT Analysis
SWOT Analysis – Overview
Valneva SE – Strengths
Valneva SE – Weaknesses
Valneva SE – Opportunities
Valneva SE – Threats
Valneva SE – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Valneva SE, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 24, 2020: Valneva provides business update on COVID-19 situation
Feb 03, 2020: Valneva announces new $85 million financing arrangement with leading US healthcare funds Deerfield and OrbiMed
Jan 09, 2020: Valneva Expands its commercial operations with the opening of its French commercial office
Dec 20, 2019: Valneva completes delisting from the Vienna Stock Exchange
Dec 12, 2019: Valneva appoints MVM Partner Thomas Casdagli to its supervisory board
Dec 09, 2019: Valneva appoints Renowned Vaccinologists Stanley Plotkin and Anna Durbin to its Scientific Advisory Board
Nov 13, 2019: Valneva announces appointments of two leading vaccine experts to its scientific advisory board
Oct 31, 2019: Valneva raises product sales guidance following strong nine-month results and R&D execution
Sep 19, 2019: Valneva Confirms Delisting from the Vienna Stock Exchange
Aug 01, 2019: Valneva reports H1 2019 results marked by strong operational performance and major corporate progress
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Valneva SE, Key Facts
Valneva SE, Key Employees
Valneva SE, Key Employee Biographies
Valneva SE, Major Products and Services
Valneva SE, History
Valneva SE, Subsidiaries
Valneva SE, Key Competitors
Valneva SE, Ratios based on current share price
Valneva SE, Annual Ratios
Valneva SE, Annual Ratios (Cont...1)
Valneva SE, Annual Ratios (Cont...2)
Valneva SE, Interim Ratios
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Valneva SE, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Valneva SE, Performance Chart (2015 - 2019)
Valneva SE, Ratio Charts
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Valneva SE (VLA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cyient Ltd (CYIENT):企業の財務・戦略的SWOT分析
    Cyient Ltd (CYIENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Cyxone AB-製薬・医療分野:企業M&A・提携分析
    Summary Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company’s lead product include T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis …
  • Waterloo Industries Inc:企業の戦略的SWOT分析
    Waterloo Industries Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Douglas Holding AG:戦略・SWOT・企業財務分析
    Douglas Holding AG - Strategy, SWOT and Corporate Finance Report Summary Douglas Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Omega Diagnostics Group Plc (ODX):企業の製品パイプライン分析
    Summary Omega Diagnostics Group Plc (Omega) is a biotechnology company that provides in-vitro diagnostic products. The company offers products in the areas of allergy, food intolerance, autoimmune disease and infectious disease, among others. It also provides food intolerance and autoimmune tests fo …
  • Reno de Medici S.p.A.:企業の戦略・SWOT・財務情報
    Reno de Medici S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Reno de Medici S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Eurus Energy Holdings Corp:電力:M&Aディール及び事業提携情報
    Summary Eurus Energy Holdings Corp (Eurus Energy), a subsidiary of Toyota Tsusho Corporation, is a renewable energy company that generates power through various renewable sources such as wind and solar photovoltaic. The company's services include location survey, wind or sunlight study, basic design …
  • Terumo Cardiovascular Systems Corporation:製品パイプライン分析
    Summary Terumo Cardiovascular Systems Corporation (TCSC), a subsidiary of Terumo Corporation, is a provider of medical equipment and devices for cardiac and vascular surgeries. It produces hardware products including heart-lung machines and intra-operative monitoring systems for cardiac surgeries. I …
  • Velesto Energy Bhd (UMWOG):石油・ガス:M&Aディール及び事業提携情報
    Summary Velesto Energy Bhd (Velesto) formerly UMW Oil & Gas Corp Bhd, a subsidiary of UMW Holdings Bhd, is an oil and gas company that offers drilling and oilfield services. The company’s services include offshore drilling, hydraulic workover services, threading, inspection and repair services. Its …
  • Commercial Metals Co:戦略・SWOT・企業財務分析
    Commercial Metals Co - Strategy, SWOT and Corporate Finance Report Summary Commercial Metals Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Lycamobile UK Limited:企業の戦略的SWOT分析
    Lycamobile UK Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Aethlon Medical Inc (AEMD):医療機器:M&Aディール及び事業提携情報
    Summary Aethlon Medical Inc (Aethlon Medical) is a developer of therapeutic technologies that address unmet needs in biodefense and global health. It develops immunotherapeutic technologies for the treatment of cancer and infectious diseases. The company’s lead product, Hemopurifier, strengthens nat …
  • GWA Group Ltd (GWA):企業の財務・戦略的SWOT分析
    GWA Group Ltd (GWA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Photocure ASA (PHO):企業の財務・戦略的SWOT分析
    Photocure ASA (PHO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Audentes Therapeutics Inc (BOLD):企業の財務・戦略的SWOT分析
    Summary Audentes Therapeutics Inc (Audentes) is a biotechnology company. It focuses on the development and commercialization of gene therapy products for rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment …
  • Enzymatica AB (ENZY):企業の財務・戦略的SWOT分析
    Summary Enzymatica AB (Enzymatica) is a life science company that develops and markets medical products for various virus and bacterial infections. The company offers mouth sprays and veterinary products. Its veterinary products comprise dental health and skin relief enzyme based gels, spray dermal …
  • Chennai Petroleum Corporation Ltd (CHENNPETRO):企業の財務・戦略的SWOT分析
    Chennai Petroleum Corporation Ltd (CHENNPETRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • The Broad Institute Inc-製薬・医療分野:企業M&A・提携分析
    Summary The Broad Institute Inc (Broad Institute), a subsidiary of The Broad Foundation, is a non-profit research organization that meets critical challenges in biology and medicine. The institute transforms medicine by utilizing systematic approaches in biological sciences, to speed up the understa …
  • Energy Metals Ltd (EME):企業の財務・戦略的SWOT分析
    Summary Energy Metals Ltd (Energy Metals) is a mining and mineral exploration company that focuses on the development of mineral resources in Australia. It acquires, explores, operates, manages, produces, and develops uranium, vanadium, and mineral resource deposit properties. Energy Metals' project …
  • Empresas Publicas De Medellin ESP:企業の戦略的SWOT分析
    Empresas Publicas De Medellin ESP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆